Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy
Affiliations
To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-alpha-2b (IFN), viral decline in 23 patients during therapy was analyzed with a mathematical model. The analysis indicates that the major initial effect of IFN is to block virion production or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. The estimated virion half-life (t1/2) was, on average, 2.7 hours, with pretreatment production and clearance of 10(12) virions per day. The estimated infected cell death rate exhibited large interpatient variation (corresponding t1/2 = 1.7 to 70 days), was inversely correlated with baseline viral load, and was positively correlated with alanine aminotransferase levels. Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 months. These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.
Mhlanga A, Wasserman O, Lampertico P, Cotler S, Dahari H JHEP Rep. 2025; 7(2):101211.
PMID: 39867682 PMC: 11758951. DOI: 10.1016/j.jhepr.2024.101211.
Beaulieu M, Guedj J J Antimicrob Chemother. 2025; 80(3):892-893.
PMID: 39799974 PMC: 11879190. DOI: 10.1093/jac/dkae447.
Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.
Kim K, Iwamoto M, Kitagawa K, Park H, Hayashi S, Tsukuda S PLoS Comput Biol. 2025; 21(1):e1012615.
PMID: 39787253 PMC: 11753647. DOI: 10.1371/journal.pcbi.1012615.
The kinetics of SARS-CoV-2 infection based on a human challenge study.
Iyaniwura S, Ribeiro R, Zitzmann C, Phan T, Ke R, Perelson A Proc Natl Acad Sci U S A. 2024; 121(46):e2406303121.
PMID: 39508770 PMC: 11573497. DOI: 10.1073/pnas.2406303121.
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.
El Messaoudi S, Brichler S, Fougerou-Leurent C, Gordien E, Gerber A, Kortebi A JHEP Rep. 2024; 6(8):101070.
PMID: 39100818 PMC: 11295569. DOI: 10.1016/j.jhepr.2024.101070.